Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
NCT04165343 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81
Last updated 2023-09-01
Summary
Evaluation of Multi-Organ Metabolism and Perfusion in Non-Alcoholic Fatty Liver Disease (NAFLD) by Total Body Dynamic PET Scan on EXPLORER
Conditions
- Non-Alcoholic Fatty Liver Disease (NAFLD)
- Nonalcoholic Steatohepatitis (NASH)
Interventions
- RADIATION
-
Positron Emission Tomography (PET) on EXPLORER
Positron Emission Tomography (PET): Your blood sugar level will be checked by a finger stick before the PET scan. A small amount of radioactive "tracer" (approximately 0.5 teaspoons) will be injected into a vein in your arm before the imaging test. You will be asked to lay on your back on the EXPLORER scanner platform with both of your arms over the head during the duration of the test. A small amount of blood (1 tablespoon) will be collected after the test. This test will last for up to one (1) hour. This is a research test. Although the results may be available it cannot be used for clinical care. If any incidental findings are noted, it will be reported to you.
- DIAGNOSTIC_TEST
-
Magnetic Resonance Imaging
MRI will be performed that can measure both the liver stiffness or fibrosis by a method called MR elastography (MRE) and the amount of fat deposited in the liver by MR proton density fat fraction (MR-PDFF). You will be asked to lay on your back on the scanner platform with both of your arms over the head during the duration of the test. MRE and MRI-PDFF are Food and Drugs Administration (FDA) approved tests and the results will be available to you. This test will last up to one (1) hour.
- DIAGNOSTIC_TEST
-
Echocardiogram and Electrocardiogram
You will have baseline echocardiogram images and electrocardiogram (ECG) taken and will be asked to walk on a treadmill, which will increase in elevation and speed every 3 minutes until you can go no longer. This usually takes 9 to 12 minutes. Immediately after exercise, echocardiogram images and ECG will be taken again. The total time you will be in the stress lab including prep time and recovery is about 60 minutes. Wear comfortable or exercise clothing and walking/running shoes. You will be asked to not eat or drink (except for water) for 4 hours prior to the time of your test. Please drink water the day of the test so you are not dehydrated. This is an FDA approved test and the results will be available to you.
- DIAGNOSTIC_TEST
-
Blood test
We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.
Sponsors & Collaborators
-
University of California, Davis
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-11-01
- Primary Completion
- 2023-05-11
- Completion
- 2023-05-11
Countries
- United States
Study Locations
More Related Trials
-
Non Alcoholic Steatohepatitis in Relation to Visceral and Subcutaneous Fat
NCT04240145 ·Status: UNKNOWN
-
Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis
NCT03142698 ·Status: UNKNOWN ·Phase: NA
-
Fatty Liver and Ectopic Fat in Overweight and Obese Patients
NCT00886301 ·Status: COMPLETED ·Phase: NA
-
Exploratory Study of MRI Biomarkers of NASH
NCT06626074 ·Status: RECRUITING ·Phase: NA
-
Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
NCT06661655 ·Status: RECRUITING ·Phase: NA
-
Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease
NCT03635541 ·Status: UNKNOWN
-
Correlation Between NAFLD, Epicardial Adipose Tissue and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)
NCT01958411 ·Status: COMPLETED
-
Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis
NCT06160271 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluation of Patients With Liver Disease
NCT00001971 ·Status: RECRUITING
-
NMR-based Metabolic Profiling Identifies High Risk of MAFLD Patients With Advanced Fibrosis
NCT05734599 ·Status: UNKNOWN
-
NAFLD Study: US vs Liver Biopsy
NCT04101162 ·Status: UNKNOWN ·Phase: NA
-
Correlation Between CEUS Identification of Nodular HPD on CE-MRI and Hepatic Malignant Lesions
NCT06816212 ·Status: ENROLLING_BY_INVITATION
-
Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
NCT01695083 ·Status: COMPLETED
-
Mitochondrial Metabolism and Hepatic Complications of Obesity
NCT03302481 ·Status: WITHDRAWN ·Phase: NA
-
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
NCT02754037 ·Status: ACTIVE_NOT_RECRUITING
-
Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome
NCT00399932 ·Status: UNKNOWN
-
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
NCT03572465 ·Status: RECRUITING
-
NASH: Non-invasive Diagnostic Markers and Imaging
NCT02717000 ·Status: UNKNOWN
-
A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease.
NCT05255978 ·Status: RECRUITING
-
Development and Validation of a Multi-target, Blood-based NAFLD Diagnosis Test
NCT05108415 ·Status: UNKNOWN
-
Central Obesity and Hepatocellular Carcinoma
NCT03082378 ·Status: UNKNOWN
-
Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)
NCT04883177 ·Status: COMPLETED
-
Characterization of the Intrahepatic Inflammatory Microenvironment in Patients With Non-alcoholic Steatohepatitis
NCT06152250 ·Status: RECRUITING ·Phase: NA
-
EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI
NCT04012021 ·Status: UNKNOWN ·Phase: NA
-
Transient Elastography in Hepatectomy for Hepatocellular Carcinoma
NCT01441453 ·Status: UNKNOWN ·Phase: NA